🚀 VC round data is live in beta, check it out!
Polaris Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Polaris Group and similar public comparables like Immix Biopharma, Opthea, Aquestive Therapeutics, Fulcrum Therapeutics and more.
Polaris Group Overview
About Polaris Group
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
Founded
2006
HQ
Employees
565
Website
Sectors
Financials (FY)
EV
$505M
Polaris Group Financials
Polaris Group reported last fiscal year revenue of $1M and negative EBITDA of ($109M).
In the same fiscal year, Polaris Group generated ($9M) in gross profit, ($109M) in EBITDA losses, and had net loss of ($124M).
Polaris Group P&L
In the most recent fiscal year, Polaris Group reported revenue of $1M and EBITDA of ($109M).
Polaris Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($9M) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (666%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($109M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (8544%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (7090%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($124M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (9672%) | XXX | XXX | XXX |
| Net Debt | — | — | $11M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Polaris Group Stock Performance
Polaris Group has current market cap of $518M, and enterprise value of $505M.
Market Cap Evolution
Polaris Group's stock price is $0.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $505M | $518M | 0.3% | XXX | XXX | XXX | $-0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPolaris Group Valuation Multiples
Polaris Group trades at 394.8x EV/Revenue multiple, and (4.6x) EV/EBITDA.
Polaris Group Financial Valuation Multiples
As of April 10, 2026, Polaris Group has market cap of $518M and EV of $505M.
Equity research analysts estimate Polaris Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Polaris Group has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $518M | XXX | $518M | XXX | XXX | XXX |
| EV (current) | $505M | XXX | $505M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 394.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.6x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (59.3x) | XXX | XXX | XXX |
| P/E | — | XXX | (4.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Polaris Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Polaris Group Margins & Growth Rates
Polaris Group's revenue in the last fiscal year declined by (62%).
Polaris Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Polaris Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (62%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (8544%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 88% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 764% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5572% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 6424% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Polaris Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immix Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Opthea | XXX | XXX | XXX | XXX | XXX | XXX |
| Aquestive Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Larimar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Polaris Group M&A Activity
Polaris Group acquired XXX companies to date.
Last acquisition by Polaris Group was on XXXXXXXX, XXXXX. Polaris Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Polaris Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPolaris Group Investment Activity
Polaris Group invested in XXX companies to date.
Polaris Group made its latest investment on XXXXXXXX, XXXXX. Polaris Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Polaris Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Polaris Group
| When was Polaris Group founded? | Polaris Group was founded in 2006. |
| Where is Polaris Group headquartered? | Polaris Group is headquartered in Taiwan. |
| How many employees does Polaris Group have? | As of today, Polaris Group has over 565 employees. |
| Is Polaris Group publicly listed? | Yes, Polaris Group is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Polaris Group? | Polaris Group trades under 6550 ticker. |
| When did Polaris Group go public? | Polaris Group went public in 2016. |
| Who are competitors of Polaris Group? | Polaris Group main competitors are Immix Biopharma, Opthea, Aquestive Therapeutics, Fulcrum Therapeutics. |
| What is the current market cap of Polaris Group? | Polaris Group's current market cap is $518M. |
| What is the current revenue of Polaris Group? | Polaris Group's last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of Polaris Group? | Current revenue multiple of Polaris Group is 394.8x. |
| Is Polaris Group profitable? | No, Polaris Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.